"TBSF" (20%) Human Albumin Solution

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

Albumin, Quantity: 200 g/L

Disponible des:

CSL Behring Australia Pty Ltd

Designació comuna internacional (DCI):

Albumin

formulario farmacéutico:

Injection, solution

Composición:

Excipient Ingredients: octanoate; sodium

Vía de administración:

Intravenous

Unidades en paquete:

50mL, 100mL

clase:

Medicine Listed (Export Only)

tipo de receta:

(S1) This Schedule is intentionally blank

indicaciones terapéuticas:

Hypoproteinaemia in the acutely ill patient TBSF (20%) Human Albumin Solution is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. Shock. TBSF (20%) Human Albumin Solution may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. Burns. Extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

Resumen del producto:

Visual Identification: Clear, slightly viscous almost colourless, yellow or green; Container Type: Vial; Container Life Time: 4 Years; Container Temperature: Store below 30 degrees Celsius

Estat d'Autorització:

Listed (Export Only)

Data d'autorització:

2006-03-01